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Aims:  Cardiac fibrosis is a major cause of heart failure, and mediated by the differentiation 
of cardiac fibroblasts into myofibroblasts.  However, limited tools are available to block 
cardiac fibrosis.  ADAMTS16 is a member of the ADAMTS superfamily of extracellular 
protease enzymes involved in extracellular matrix degradation and remodeling.  In this study, 
we aimed to establish ADAMTS16 as a key regulator of cardiac fibrosis.  
 
Methods and Results:  Western blot and qRT-PCR analyses demonstrated that ADAMTS16 
was significantly up-regulated in mice with transverse aortic constriction (TAC) associated 
with left ventricular hypertrophy and heart failure, which was correlated with increased 
expression of Mmp2, Mmp9, Col1a1 and Col3a1.  Overexpression of ADAMTS16 
accelerated the AngII-induced activation of cardiac fibroblasts into myofibroblasts.  Protein 
structural analysis and co-immunoprecipitation revealed that ADAMTS16 interacted with the 
latency-associated peptide (LAP)-TGF-β via a RRFR motif.  Overexpression of 
ADAMTS16 induced the activation of TGF-β in cardiac fibroblasts, however, the effects 
were blocked by a mutation of the RRFR motif to IIFI, knockdown of Adamts16 expression 
or a TGF--neutralizing antibody (Ab).  The RRFR tetrapeptide, but not control IIFI 
peptide, blocked the interaction between ADAMTS16 and LAP-TGF-β, and accelerated the 
activation of TGF-β in cardiac fibroblasts.  In TAC mice, the RRFR tetrapeptide aggravated 
cardiac fibrosis and hypertrophy by upregulation of extracellular matrix proteins, activation 
of TGF-β, and increased SMAD2/SMAD3 signaling, however, the effects were blocked by 
TGF--NAb.   
    
Conclusions:  ADAMTS16 promotes cardiac fibrosis, cardiac hypertrophy and heart failure 
by facilitating cardiac fibroblasts activation via interacting with and activating LAP-TGF-β 
signaling.  The RRFR motif of ADAMTS16 disrupts the interaction between ADAMTS16 
and LAP-TGF-β, activates TGF-β, and aggravated cardiac fibrosis and hypertrophy.  This 
study identifies a novel regulator of TGF-β signaling and cardiac fibrosis, and provides a new 
target for the development of therapeutic treatment of cardiac fibrosis and heart failure.  
 











Transforming growth factor (TGF)-β is a master cytokine/growth factor crucially involved in 
many biological processes such as embryogenesis, angiogenesis, and immune modulation and 
multiple fibrotic human diseases.1, 2  TGF-β mediates its biological effects by binding to its 
receptors TGFβRI/TGFβRII, and phosphorylating SMAD2 and SMAD3 transcription factors, 
which are then translocated into the nucleus, and activate transcription of target genes.3  
However, the most important checkpoint for TGF-β signaling is at the stage of the activation 
of TGF-β, a process converting the latent precursor (latency associated peptide (LAP)-TGF-β) 
to the mature, biologically active TGF-β.  The LAP domain is cleaved first from the mature 
TGF-β, however, the two regions remain associated with each other, preventing receptor 
binding and signaling and leaving only a small fraction of TGF-β biologically active.  The 
molecular mechanisms for activation of latent TGF-β are not well understood.  Proteolysis 
by plasmin, binding to some integrins, oxidative modifications, and interaction with the 
extracellular matrix (ECM) protein thrombospondin 1 (TSP-1) were reported to activate 
latent TGF-β.2  Blockade of disease-associated TGF-β activation by targeting the latent 
TGF-β activation mechanism represents a selective approach to develop novel therapeutic 
strategies to treat related diseases.   
Heart failure (HF) is a major public health problem, affecting 26 million people 
worldwide.4  However, the 5-year survival rate for HF is 25%-52%, which is worse than 
most cancers.5  Cardiac fibrosis is the major factor in the development of HF.  Anti-fibrotic 
therapy is considered to be beneficial in alleviating HF.6, 7  Excessive accumulation of ECM 
components leads to fibrosis.8, 9  Cardiac fibrosis is predominantly mediated by the 
activation of cardiac fibroblasts, which is a process of conversion from the tissue-resident 
fibroblasts to proliferating, fibrogenic, and contractile myofibroblasts with increased 
expression of genes such as ACTA2 (encoding -smooth muscle actin, SMA).8, 10  
Moreover, myofibroblasts also drive ECM remodeling by producing and secreting matrix 
metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs).8  The TGF-β 
expression level is elevated in response to injury11-13, and TGF-β signaling is associated with 
repair and fibrosis of different tissues.11-13  In particular, TGF-β plays a pivotal role in 
fibroblast activation and ECM production.9, 11  To date, no clinical therapies are available to 
effectively block cardiac fibrosis without side effects.  Therefore, additional new regulators 
of cardiac fibrosis need to be identified to facilitate development of novel therapeutic 
strategies targeting cardiac fibrosis.    
ADAMTS16 is one of 19 members of the ADAMTS family of metalloproteinases 
involved in diverse biological processes, including spermatogenesis/fertilization, 
neurogenesis, inflammatory responses and cancer.14, 15  ADAMTS16 was shown to be 
involved in premature ovarian failure, male genitourinary system dysfunction, esophageal 
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ADAMTS16 in cardiac fibrosis and heart failure is unknown.  
In this study, we identify ADAMTS16 as a novel regulator of cardiac fibrosis.  
ADAMTS16 is upregulated in a mouse model for cardiac hypertrophy and heart failure, and 
its expression is strongly correlated with markers for cardiac fibrosis and the activation of 
cardiac fibroblasts.  We show that ADAMTS16 promotes cardiac fibrosis by interaction with 
the latent form of TGF-β, which leads to TGF-β activation.  Furthermore, we show that 
cardiac fibrosis in TAC mice is accelerated by treatment with a tetrapeptide RRFR peptide 
derived from ADAMTS16.  The RRFR peptide activates TGF-β, promotes the activation of 
cardiac fibroblasts and cardiac fibrosis, and exacerbates cardiac hypertrophy and heart failure. 
The effect of ADAMTS16 overexpression on activation of TGF-β and the effect of the RRFR 
peptide on cardiac fibrosis and hypertrophy were all blocked by a TGF-β-neutralizing 
antibody. Taken together, these data suggest that modulating ADAMTS16, in particular, the 
RRFR motif, may become a powerful new strategy to attenuate cardiac fibrosis and treat 
patients with HF.    
 
2. Methods 
2.1 Plasmids antibodies and peptides  
The expression plasmids for ADAMTS16, pcDNA-4 ADAMTS16-FLAG-C14 or 
pCDNA4-ADAMTS16-FLAG-C2, were described previously.22  The coding region of 
ADAMTS16 was PCR-amplified from pcDNA-4 ADAMTS16-FLAG-C14 and subcloned into 
pcDNA3.1, resulting in another expression plasmid for ADAMTS16, pcDNA3.1-ADAMTS16.  
A mutation of the RRFR motif to IIFI was created in pcDNA3.1-ADAMTS16 using the 
PCR-based mutagenesis, resulting in an expression plasmid for pcDNA3.1-ADAMTS16-IIFI.    
An expression plasmid for TGFB1 was constructed by amplification of the coding by 
PCR using human cDNA samples and subcloning into the N-terminal p3*flag-cmv vector 
(pcDNA3.1-Flag-LAP-TGF-).     
A rabbit anti-ADAMTS16 antibody was purchased from Abcam (Cambridge, MA, USA) 
(ab45048, 1:1000 dilution for Western blotting).  A rabbit anti--Tubulin antibody was 
purchased from Proteintech (Wuhan, Hubei, China) (10068-1-AP, 1:1000 dilution for Western 
blotting).  A rabbit anti-phosphorylated SMAD3 (Ser423+Ser425) antibody was from Bioss 
(Beijing, China) (bs-3425R, 1:500 dilution for Western blotting).  An antibody for 
phosphorylated SMAD2 (Ser465/467) was from Cell Signaling Technology (Boston, MA, 
USA) (#3101, 1:1000 dilution for Western blotting).  A rabbit anti-Flag antibody was from 
MBL life science (PM020, 1:1000 dilution for Western blotting). A TGF-neutralizing 
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The RRFR tetrapeptide from ADAMTS16 and negative control peptide IIFI were 
synthesized by GENEWIZB (Wuhan, China). 
 
2.2 Isolation of mouse cardiac fibroblasts (MCFs), cardiomyocytes culture and 
transfection  
Neonatal mouse cardiac fibroblasts (MCFs) were prepared from hearts of 1- to 2-day-old 
C57BL/6 mice by digestion with 0.1% (w/v) collagenase type II (Worthington) for 30 min at 
37°C as described previously.23 The cells were cultured in Iscove's Modified Dulbecco's 
Medium (IMDM, Gibco) with 10% (v/v) fetal bovine serum (FBS), 100 U/mL penicillin G, 
and 100 μg/mL streptomycin.  After 4 hours of culture, the non-adherent cells were washed 
off.  The isolated MCFs were cultured in the Dulbecco’s Modified Eagle’s medium (DMEM) 
with high-glucose supplemented with 10% (v/v) FBS (Gibco Life Technologies, Gaitherburg, 
MD, USA) in a humidified incubator with 5% (v/v) CO2 at 37°C. Cardiomyocytes were 
isolated from mice as previously described.24 
MCFs were transfected with plasmid DNA (1-2 g) and siRNA (100 nM) using the 
FuGENE HD Transfection Reagent (Roche, Indianapolis, IN, USA) according to the 
manufacturer’s instruction.  The siRNAs targeting the Adamts16 mRNA sequence and 
negative control siRNA (siNC) were chemically synthesized by RiboBio (Guangzhou, 
Guangdong, China).  The siNC does not have homology to any known gene sequences from 
humans and mice.  The sequences of siAdamts16 duplexes were 5’- 
GAAGACGCAAGAAAUACAUTT-3’ (sense). 
 
2.3 Luciferase assays  
HeLa cells were plated in a 24-well plate and transfected with a 3TP-Luc reporter construct 
and pRL-TK with or without an ADAMTS16 expression plasmid using Fugene HD as 
described.25-28  30 hours later, cells were used for luciferase assays using the Dual 
Luciferase Reporter Assay System (Promega, Madison, WI, USA) as described by us 
previously.25-28  Luciferase activities were normalized to Renilla luciferase activity.     
 
2.4 ELISA for quantification of TGF- 
To measure the amount of TGF- in the supernatant of cell culture of MCFs, an ELISA was 
performed using the mouse TGF-β1 Quantikine ELISA Kit (R&D Systems, Minneapolis, 
MN, USA) according to the manufacturer’s recommendations.  Standard curves were 
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2.5 Animal procedures  
C57BL/6 mice (12-week-old) were used for all animal studies. Animal care and experimental 
procedures were approved by the Ethics Committee on Animal Research of Huazhong 
University of Science and Technology. All animal experiments conform to the guidelines 
from Directive 2010/63/EU of the European Parliament on the protection of animals used for 
scientific purposes.   
Pressure overload of the heart was induced in 12-week-old male mice (20–25 g) by 
transverse aortic constriction (TAC) as described.7  The mice were injected intraperitoneally 
with the RRFR peptide (0.25 mg/kg body weight) or the same dose of negative IIFI peptide 
(0.25 mg/kg body weight) twice a week for 8 weeks. TGF- Ab and control IgG were 
injected intraperitoneally into mice at the dose of 10 mg/kg body weight twice a week for 8 
weeks.  Echocardiography was performed by an operator who was blinded to treatments as 
described.29-31  After study, all animals were anesthetized with an intraperitoneal injection of 
sodium pentobarbital (50 mg/kg) and then euthanized by cervical dislocation.  
 
2.6 Quantitative Real-time RT-PCR analysis  
Total RNA was extracted from cultured cells or mouse hearts using Trizol (Invitrogen), and 2 
g of RNA samples were used for quantitative real-time PCR analysis with the FastStart 
Universal SYBR Green Master (Roche, Basel, BS, Switzerland) as described previously.32, 33 
Experiments were performed in triplicate and repeated at least three times.  
 
2.7 Western blot analysis and Co-immunoprecipitation (Co-IP)  
Western blot analysis was carried out using protein extracts from transfected cells and mouse 
hearts as described.  Western blot images were captured and quantified using 1-D Analysis 
Software and Quantity One (Bio-Rad, Hercules, CA, USA).7, 29, 31   
For Co-IP, MCFs were transfected with pcDNA3.1-ADAMTS16 and 
pcDNA3.1-Flag-LAP-TGF- for 48 hours, and lysed with pre-cooled lysis buffer (50 mM 
Tris/HCl, pH 7.5, 150 mM NaCl, 2 mM EDTA, 1% (v/v) Nonidet P-40, proteinase inhibitor 
cocktail).  The cell extracts were pre-adsorbed with 30 μL of Protein A/G PLUS-agarose 
(SantaCruz, TX, USA) for 4 hours at 40C and used for Co-IP with anti-FLAG recognizing 
LAP-TGF- and anti-ADAMTS16 antibodies as described.34   
 
2.8 Immunohistological analysis and immunostaining  
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paraffin-embedded, and sectioned.  Heart sections were stained with Masson staining and 
Typical Sirius Red staining as described.29, 30  Immunostaining was performed with MCFs 
for -SMA staining as described.29, 30   
 
2.9 Cell migration assays  
Migration assays with cardiac fibroblasts were carried out as previously described.24  In 
brief, cardiac fibroblasts were plated in 6-well plates for 24 h and transfected with 
pcDNA3.1-ADAMTS16 or pcDNA3.1, and then a wound was made by mechanical scratch 
with a pipette tip.  Cells were incubated with angiotensin II (Ang II, 1 μM) or vehicle for 24 
h, and cell migration was quantified according to the ratio of cell coverage to the acellular 
area.   
 
2.10 Collagen contraction assay 
Cardiac fibroblasts were transfected with pcDNA3.1-ADAMTS16 or pcDNA3.1 for 24 h. 
Cells were then trypsinized, counted and added to a collagen solution (Shengyou 
Biotechnology, Hangzhou, China).  The cell collagen mixture was grown in 96 well culture 
plates, and then incubated for 1 h under standard conditions for polymerization of collagen 
cell lattices. The culture medium containing Ang II (1 μM) or vehicle were added. After 8, 16 
or 24 hours, the collagen lattice area was measured to calculate the relative contraction ratio 
of gel contraction.35 
 
2.11 Statistical analysis  
All quantitative data were shown as mean±s.d. The difference between two groups of 
variables was compared by the two-tailed, paired or unpaired Student’s t-test. For 
comparisons of more than two groups, one-way analysis of variance was employed for 
normal distributions and the Kruskal-Wallis test for non-normal or small samples. A P value 
of < 0.05 was considered as significant.   
 
3. Results 
3.1 ADAMTS16 expression is up-regulated in a TAC model for cardiac hypertrophy and 
heart failure  
To characterize the role of ADAMTS16 in cardiac fibrosis and heart failure, we created the 
transverse aortic constriction (TAC) model in 12-week-old C57BL/6 mice to induce LV 
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used for Western blotting and real-time RT-PCR analyses.  The expression levels of both the 
ADAMTS16 protein and the Adamts16 mRNA were significantly higher in the hearts from 
TAC mice than in control sham hearts (Figure 1A-C). To identify cell type–specific 
expression changes of Adamts16 in normal and pressure-overload hearts, we isolated 
cardiomyocytes and cardiac fibroblasts from TAC and sham mice. Real-time RT-PCR 
analysis showed a significantly increased Adamts16 mRNA level in cardiac fibroblasts but 
not in cardiomyocytes from TAC mice compared to sham mice (Supplementary material 
online, Figure S1). 
 
3.2 Up-regulation of ADAMTS16 is associated with cardiac fibrosis and activation of 
cardiac fibroblasts  
Mmp2 and Mmp9 are involved in pathogenesis of cardiac fibrosis and hypertrophy by 
regulating ECM homeostasis.36-38 Real-time RT-PCR analysis with cardiac RNA samples 
showed that up-regulation of Adamts16 was strongly correlated with the increased expression 
levels of Mmp2 (r=0.8355, P<0.05) and Mmp9 (r=0.7817, P<0.05) in TAC mice (Figure 1D).  
MMP2 and MMP9 are involved in processing several different collagen types.39 Similarly, 
up-regulation of Adamts16 was significantly correlated with the increased expression levels 
of Col1a1 (r=0.7541, P<0.05) and Col3a1 (r=0.7945, P<0.05) in TAC mice (Figure 1D). 
One key molecular mechanism for cardiac fibrosis is the phenotypic differentiation of 
fibroblasts into myofibroblasts, which is marked with increased expression of -SMA 
encoded by the Acta2 gene.9  We overexpressed ADAMTS16 in isolated primary neonatal 
mice cardiac fibroblasts (MCFs) treated with Angiotensin II (Ang II).  Consistent with the 
pro-fibrotic effects of AngII, real-time RT-PCR analysis showed that the expression level of 
the myofibroblast marker Acta2 was significantly increased by AngII (Figure 2A), and 
interestingly, overexpression of ADAMTS16 further increased Acta2 expression significantly 
at the mRNA level (Figure 2A).  The interesting finding of upregulation of the 
myofibroblast marker by overexpression of ADAMTS16 was confirmed at the protein level of 
-SMA using immunostaining and Western blot analysis (Figure 2B-E). We also 
characterized the functional effect of ADAMTS16 on contractile capability of MCFs. 
Overexpression of ADAMTS16 significantly increased the contraction of collagen matrices, 
an indicator for contraction capacity of MCFs (Figure 2F and G). A wound healing assay 
showed that overexpression of ADAMTS16 significantly increased the migration of MCFs 
(Figure 2H and I). Together, these data suggest that ADAMTS16 overexpression induces the 
activation of MCFs.   
 
3.3 ADAMTS16 interacts with the latent form of TGFβ (LAP-TGF-β) 
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carefully analyzed the protein structure of ADAMTS16, and found that it has multiple 
thrombospondin type 1 (TSP1) motifs (Figure 3A).  Structural modeling analysis showed 
that the first TSP1 motif spanning amino acid residues 587-667 of ADAMTS16 
(SWISS-MODEL: https://swissmodel.expasy.org/) resembles the TSP1 motif of TSP1 
(Figure 3B and C).  TSP1 was shown to interact with LAP-TGF-β through a KRFK motif 
and a WxxW motif (WSPW, WSHW, WGPW).40  A similar, although not identical, WxxW 
motif was identified in the TSP1 motif of ADAMTS16 (Figure 3C).  We did not identify the 
KRFK motif in ADAMTS16, but found an RRFR motif which shares similar charged amino 
acid residues with KRFK (Figure 3C).  We hypothesized that ADAMTS16 interacts with 
LAP-TGF-β through the WxxW and RRFR motifs (Figure 3D).  We co-expressed 
ADAMTS16 and FLAG-tagged LAP-TGFβ in HeLa cells for Co-IP analysis.  An 
anti-ADAMTS16 antibody successfully precipitated FLAG-tagged LAP-TGF-β from HeLa 
cell extracts (Figure 3E), whereas an anti-FLAG antibody precipitated ADAMTS16 (Figure 
3F).  These data demonstrate the interaction between ADAMTS16 and LAP-TGF-β.  
 
3.4 ADAMTS16 induces the activation of TGF- 
TGF-β activation is indicated by cleavage of the LAP domain from LAP-TGF-β and the 
release of mature TGF-β.  To determine the effect of ADAMTS16 on the activation of 
LAP-TGF-β, MCFs were co-transfected with an expression plasmid for LAP-TGF-β with or 
without an ADAMTS16 expression plasmid and used for Western blot analysis.  Moreover, 
we tested the effect of the RRFR motif on ADAMTS16 activation of TGF-β because the 
KRFK motif, but not the WXXW motif, of TSP1 was found to activate LAP-TGF-β.41  
Overexpression of ADAMTS16 decreased the level of LAP-TGF-β (Figure 4A), however, 
the effect was abolished by mutating the RRFR motif to IIFI motif (Figure 4B and C).  
Co-IP showed that the mutant ADAMTS16 with IIFI reduced the interaction between 
ADATS16 and LAP-TGF-β (Figure 4D).  These data suggest that the RRFR motif can 
mediate the interaction between ADAMTS16 and LAP-TGF-β and their functional effects.    
The activation of TGF-β was directly measured by an ELISA in the supernatant of MCF 
culture.  Overexpression of WT ADAMTS16 markedly increased the amount of active 
TGF-β released in the culture, however, the effect was abolished by the mutant ADAMTS16 
with the IIFI mutation (Figure 4E).  No significant difference was observed for total 
TGF-β1 (acid treated) (Figure 4F). A sensitive luciferase assay was also used to measure the 
level of TGF-β activation by measuring TGF-β-mediated promoter activation.  A 
TGF-β-responsive TPE-luciferase reporter gene was co-transfected in HeLa cells with 
WT-ADAMTS16 or Mut-ADAMTS16, and used for luciferase assays. TGF-β1 treatment 
(positive control) and overexpression of WT ADAMTS16 significantly increased 
TGF-β-dependent transcription activation (Figure 4G and Supplementary material online,  
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TGF-β NAb (Figure 4G, H and Supplementary material online, Figure S2). 
To further confirm the important role of ADAMTS16 in TGF-β activation, we knocked 
Adamts16 expression down in MCFs using siRNA (Figure 4I and Supplementary material 
online,  Figure S3).  Knockdown of Adamts16 increased the level of LAP-TGFβ (Figure 
4I), dramatically decreased the level of active and secreted TGF-β (Figure 4J) and 
significantly reduced TGF-β-dependent transcription activation (Figure 4L). No significant 
difference was observed for total TGF-β1 (acid treated) (Figure 4K).   
 
3.5 An RRFR tetrapeptide induces TGF-β activation 
Because the RRFR motif of ADAMTS16 is required for binding to and activation of TGF-β 
in MCFs, we hypothesized that a RRFR tetrapeptide mimicked the function of ADAMTS16 
and plays a critical role in TGF-β activation.  MCFs were co-expressed with ADAMTS16 
and LAP-TGF-β and incubated with different doses of the RRFR peptide.  Co-IP showed 
that the RRFR peptide reduced the interaction between ADAMTS16 and LAP-TGF-β 
(Figure 5A), which further suggests that the RRFR motif of ADAMTS16 is responsible for 
the interaction between ADAMTS16 and LAP-TGF-β.  Western blot analysis showed that 
the RRFR peptide significantly reduced the level of LAP-TGF-β, an indication for the 
activation of TGF-β (Figure 5B).  An ELISA showed that the RRFR peptide, but not the 
IIFI peptide, significantly increased the release of mature TGF-β in MCF culture media 
(Figure 5C), and induced TGF-β-dependent transcription activation (Figure 5D).  In 
addition, the effect of the RRFR peptide was independent of ADAMTS16 as similar results 
were obtained in MCFs treated with Adamts16 specific siRNA or negative control siRNA 
(siNC) (Figure 5C and D).   
 
3.6 The RRFR tetrapeptide accelerates cardiac hypertrophy 
As the RRFR peptide significantly increased the activation of TGF-β in MCFs (Figure 5), we 
hypothesized that the RRFR peptide would promote cardiac hypertrophy in mice.  
12-week-old male TAC mice were treated with intraperitoneal injection of the RRFR peptide 
(0.25 mg/kg; PBS as negative control) twice a week for 8 weeks. Treatment with the RRFR 
peptide, aggravated cardiac hypertrophy in TAC mice compared with PBS control, however, 
the effect was significantly attenuated by TGF-β1 NAb (Figure 6A). Echocardiography 
showed that the RRFR peptide aggravated cardiac dysfunction in TAC mice by decreasing 
LVEF compared with PBS control, however, the effect was significantly attenuated by 
TGF-β1 NAb (Figure 6B).  Similarly, the RRFR peptide significantly increased the ratio of 
HW/HL compared with PBS control, however, the effect was significantly attenuated by 
TGF-β1 NAb (Figure 6C). On the other hand, RRFR treatment did not have significant effect 
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the RRFR peptide treatment than PBS control, however, the effect was significantly 
attenuated by TGF-β1 NAb (Figure 6E).  To determine whether there is a sex difference, 
similar studies as above were performed for female mice.  Interestingly, similar results as 
found in male mice were obtained in female mice (Supplementary material online, Figure 
S4 A-E). All together, these data suggest that the RRFR peptide derived from ADAMTS16 
promotes cardiac hypertrophy and heart failure, but the effects were abolished by TGF-β1 
NAb, suggesting that the RRFR peptide promotes cardiac hypertrophy and heart failure by 
activating the TGF-β signaling pathway.    
   
3.7 The RRFR tetrapeptide accelerates cardiac fibrosis 
To identify the molecular mechanism by which the RRFR tetrapeptide promotes cardiac 
hypertrophy and heart failure, we analyzed its effects on cardiac fibrosis because TGF-β 
plays a key role in cardiac fibrosis.  In TAC mice 8 weeks after the TAC surgery, Masson 
staining showed that the RRFR peptide significantly aggravated TAC-induced myocardial 
fibrosis (collagen content) compared with PBS control, however, the effect was significantly 
attenuated by TGF-β1 NAb (Figure 7A-C). Similar findings were obtained with Sirius red 
staining (Figure 7A-C).  Moreover, the RRFR peptide significantly increased the expression 
levels of Col1a1, Col1a3, Mmp2 and Mmp9 mRNA after TAC compared with PBS control, 
however, the effect was significantly attenuated by TGF-β1 NAb (Figure 7D-G).     
TGF-β activation was shown to activate SMAD2/3 (increased phosphorylation), which 
accelerates cardiac fibrosis, and causes cardiac hypertrophy.42  Interestingly, we found that 
the RRFR peptide increased SMAD2/3 phosphorylation in hearts from male TAC mice 
compared with the PBS control, however, the effect was significantly attenuated by TGF-β1 
NAb (Figure 7H-J). Similar results as found in male mice were obtained in female mice 
(Supplementary material online, Figure S5 A-G). Taken together, these results support the 
notion that the RRFR motif of ADAMTS16 plays a pivotal role in cardiac fibrosis by 
activating TGF-β signaling (Figure 7K).   
 
3.8 TAC affects the expression levels of other members of the ADAMTS family  
There are 19 members in the ADAMTS family.  We hypothesized that as with Adamts16, 
other Adamts genes may show expression differences between TAC mice and sham mice.  
Real-time RT-PCR analysis showed that the expression level of Adamts7 was significantly 
up-regulated in TAC hearts as compared to control sham hearts to the same level as Adamts16 
(Supplementary material online, Figure S6).  Adamts13 was also significantly 
up-regulated in TAC hearts compared with sham hearts, but not to the scale of Adamts7 or 
Adamts16 (Supplementary material online, Figure S6).  On the other hands, the 
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down-regulated in TAC hearts as compared to control sham hearts (Supplementary material 
online, Figure S6). Adamts18 showed the highest down-regulation in TAC mice.   
 
4. Discussion 
Cardiac fibrosis contributes critically to cardiac dysfunction in patients with a hypertensive 
heart and heart failure by causing structural and functional remodeling.43 Therefore, the 
reduction of cardiac fibrosis by targeting novel regulators of cardiac fibrosis is considered to 
be an effective strategy for clinical treatment of heart failure.9  In this study, we showed that 
ADAMTS16 is a novel regulator of activation of cardiac fibroblast, TGF-β signaling, and 
cardiac fibrosis.  The expression level of ADAMTS16 was significantly up-regulated in 
mouse hearts with pressure-overload-induced cardiac hypertrophy and HF associated with 
cardiac fibrosis (Figure 1A and B).  In addition, we found significant and strong correlation 
of the expression level of Adamts16 with that of Mmp2, Mmp9, Col1a1, and Col3a1 in the 
hearts of TAC mice (Figure 1C). Overexpression of ADAMTS16 triggered MCF activation, 
proliferation, contraction and migration induced by AngII (Figure 2).  Under pressure 
overload, TGF-β is the central player in cardiac fibrosis accompanied by the activation of 
fibroblasts, leading to the remodeling and deposits of ECM proteins, such as different types 
of collagen and fibronectin9, 44. Recent clinical studies have demonstrated an increased 
myocardial TGF-β expression level during cardiac hypertrophy and fibrosis.45  Our results 
demonstrate that ADAMTS16 interacts with LAP-TGF-β via an interesting RRFR motif, 
which promotes the release of the LAP from LAP-TGF-β, converting the latent form of 
LAP-TGF-β to the active form of TGF-β (Figure 3).  Moreover, increased ADAMTS16 
expression contributes to TGF-β-dependent transcriptional activities (Figure 4).  The effect 
was inhibited by TGF--NAb (Figure 4H and Supplementary material online, Figure S2), 
indicating an important regulatory role of TGF- signaling in functions of ADAMTS16.  We 
showed that intraperitoneal injection of the RRFR peptide derived from ADAMTS16 
aggravated cardiac fibrosis, hypertrophy and dysfunction in TAC mice, however, the effects 
were inhibited by TGF--NAb (Figures 6 and 7).  The in vivo data again suggest that 
TGF- signaling mediates functions of ADAMTS16.  A schematic diagram showing the 
regulation and function of ADMTS16 in cardiac fibrosis/hypertrophy and heart failure is 
shown in Figure 7E.  TGF-β was previously found to stimulate the expression of 
endogenous ADAMTS16,22 whereas we found here that ADAMTS16 activates TGF-β.  The 
two proteins may form an interesting feed forward loop which exacerbates cardiac 
hypertrophy and heart failure.   
ADAMTS16 was previously shown to control blood pressure by regulating the aortic 
pulse wave velocity, vascular media thickness, glomerular filtration rate, renal hemodynamics 
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Our finding that ADATMTS16 activates TGF-β provides a novel potential molecular 
mechanism for the regulation of blood pressure by ADAMTS16.  Zacchigna et al found that 
knockout of Emilin1 increased blood pressure and peripheral vascular resistance, and reduced 
vessel size in mice.46  Emilin1 was found to inhibit TGF-β signaling, and inactivation of a 
single TGFB1 allele rescued the high blood pressure phenotype in Emilin1 knockout mice.46  
Therefore, it appears that Emilin1 knockout mice developed hypertension because of 
activated TGF-β.  Similarly, knockout of Adamts16 inhibits TGF-β activation, thereby 
reducing blood pressure in mutant rats with a 17 bp deletion in exon 1 of Adamts16.21  
ADAMTS16 was also shown to be involved in the development of the testis, premature 
ovarian failure, male genitourinary system dysfunction, esophageal squamous cell carcinoma, 
and optic fissure (OF) closure.16-21, 47  The results in this study identify a novel function for 
ADMTS16 in cardiac hypertrophy and HF.   
ADAMTS16 is one of 19 members of the ADAMTS family of metalloproteinases21. 
Typical functions of the ADAMTS proteases include processing of procollagens, von 
Willebrand factor, aggrecan, versican, brevican and neurocan, resulting in the turnover and 
remodeling of ECM.48, 49  The data in this study indicate a non-canonical function of 
ADAMTS16 in promoting the activation of TGF-β and related activities, resulting in the 
differentiation of cardiac fibroblasts to myofibroblasts and increased proliferation.  
Several ADAMTS metalloproteinases have been shown to play an important role in 
cardiovascular diseases. We found that the expression levels of Adamts7, Adamts13 and 
Adamts16 were significantly up-regulated in TAC hearts, whereas Adamts2, Adamts6, 
Adamts15 and Adamts18 were down-regulated by TAC (Supplementary material online, 
Figure S6). Interestingly, Adamts7 and Adamts16 were up-regulated by TAC to the similar 
level (Supplementary material online, Figure S6), and only the ADAMTS7 and 
ADAMTS16 proteins share the homologous amino acid sequences at the WxxW and 
KRFK/RRFR motifs.  Genomic variants in ADAMTS7 were significantly associated with 
risk of coronary artery disease (CAD) and acute myocardial infarction (AMI) in humans, 
and knockout of Admts7 reduces atherosclerosis in mice.50  Wang et al recently showed 
that knockout of Adamts2 exacerbated cardiac hypertrophy in TAC mice, and cardiac 
specific overexpression of Adamts2 in mice attenuated cardiac hypertrophy.51  The 
proposed mechanism is the inhibition of PI3K/AKT signaling in cardiomyocytes by 
ADAMTS2.  Although both ADAMTS16 and ADAMTS2 are involved in regulation of 
cardiac hypertrophy and HF, they act in completely different manners.  First, the two 
metalloproteinases confer opposite effects on cardiac hypertrophy, with ADAMTS16 as a 
risk factor and ADAMTS2 as a protective factor.  This is consistent with our expression 
data showing that Adamts16 was up-regulated in TAC hearts, whereas Adamts2 was 
down-regulated (Supplementary material online, Figure S6).  Second, ADAMTS2 
regulates cardiac hypertrophy by inhibiting the PI3K/AKT signaling in cardiomyocytes, 
whereas ADAMTS16 activates TGF-β signaling in cardiac fibroblasts and promotes 
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interesting to investigate the role of other members of the Adamts gene family showing 
either up-regulation or down-regulation in TAC hearts in cardiac fibrosis, hypertrophy and 
heart failure in the future.  It is particularly interesting to characterize Adamts18 for its 
role in cardiac fibrosis, hypertrophy and heart failure as it showed the highest 
down-regulation in TAC mice.     
Gunes et al studied the expression levels of ADAMTS16 in thoracic aorta tissue samples 
from human patients with thoracic aortic aneurysms (TAA) and thoracic aortic dissection 
(TAD) versus age-matched controls using Western blot analysis.19  Mutations in multiple 
gene/protein components of the TGF-β signaling pathway were found to cause TAA and 
TAD.52  In this study, we found that ADAMTS16 interacts with LAP-TGF-β, which leads to 
the activation of TGF-β (Figure 3), increased TGF-β signaling, and increased 
TGF-β-dependent transcriptional activities (Figure 4).  Therefore, it should be interesting to 
further investigate whether upregulation of ADAMTS16 in TAA and TAD aortic tissue 
samples may cause TAA and TAD by regulating TGF-β signaling.       
TGF-β is a strong inducer of cardiac hypertrophy.53  Some studies suggested that TGF-β 
was secreted from cardiac fibroblasts, and induces the secretion of connecting tissue growth 
factor (CTGF) from cardiomyocytes; CTGF from cardiomyocytes induces cardiomyocyte 
hypertrophy following pressure overload via the AKT pathway in a cell-autonomous 
manner.53, 54  Another study showed that beta-adrenergic signaling was activated in 
TGF-β-transgenic mice, leading to increased cardiac hypertrophy.55  Therefore, ADAMTS16 
may also regulate cardiac hypertrophy and heart failure by regulating TGF-β, CTGF, and 
AKT functions in cardiomyocytes.   
TSP1 was found to interact with and activates LAP-TGF-β.2  Subsequent studies 
showed that the KRFK motif of TSP1 was critical for interaction with the LSKL motif of the 
LAP-TGF-β, disrupting LAP-mature domain interactions so that the receptor binding 
sequences are exposed for TGF-β signaling.2  ADAMTS16 does not have the exact KRFK 
motif of TSP1, however, a motif of RRFR was found and shown to mediate the interaction 
between ADAMTS16 and LAP-TGF-β (Figures 3 and 4).  In vivo mouse studies showed 
that intraperitoneal injection of the RRFR peptide promoted cardiac fibrosis and exacerbates 
cardiac hypertrophy in TAC mice (Figures 6 and 7).  These data suggest that the 
ADAMTS16 RRFR motif is a new therapeutic target for treatment of cardiac fibrosis, cardiac 
hypertrophy and heart failure.  Future studies may develop therapeutic monoclonal 
antibodies against the RRFR motif of ADAMTS16 to block the interaction between 
ADAMTS16 and LAP-TGF-β, which may inhibit the activation of TGF-β signaling and 
block cardiac fibrosis.  Other types of inhibitors against ADAMTS16 function, for example, 
small chemical inhibitors, may also inhibit cardiac fibrosis and treat cardiac hypertrophy and 
HF.  In addition, TGF-β is known as the most potent pro-fibrogenic cytokine and involved in 
many other fibrotic diseases, including renal fibrosis, pulmonary fibrosis, liver fibrosis and 
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become a novel treatment of many other fibrotic diseases.  
Our study has several limitations.  First, although studies in cultured cardiac fibroblasts 
suggest an important role of ADAMTS16 in activation of cardiac fibroblasts and TGF- 
activation, and exogenous infusion of the RRFR peptide from ADAMTS16 enhanced cardiac 
hypertrophy and fibrosis, the in vivo role of endogenous Adamts16 remains to be established.  
Global knockout (KO) mice deficient in Adamts16, and cardiomyocyte-specific or cardiac 
fibroblasts-specific KO mice can be developed to demonstrate the critical role of Adamts16 in 
cardiac fibrosis and hypertrophy, and distinguish the specific cell type(s) involved.  Second, 
the interaction between endogenous ADAMTS16 and LAP-TGF- in primary cardiac 
fibroblasts cells needs to be further analyzed.  Third, it may be interesting to determine 
whether the expression level of ADAMTS16 is affected in human hearts with heat failure.   
In conclusion, we show that ADAMTS16 is a central activator of TGF-β to accelerate 
activation of cardiac fibroblasts.  Furthermore, the RRFR motif in ADAMTS16 plays a key 
role in the activation of TGF-β signaling.  Our data in mouse models showed that the RRFR 
peptide from ADAMTS16 treatment aggravated TAC-induced cardiac fibrosis, hypertrophy 
and heart failure, also by regulating TGF-β signaling.  Together, we demonstrated that the 
RRFR motif of ADAMTS16 is a key player in the dynamic interplay that regulates TGF-β 
activation.  As TGF-β signaling is involved in numerous fibrotic diseases, the development 
of inhibitors or neutralizing antibodies of ADAMTS16 or the RRFR motif may serve as a 
new strategy to treat not only cardiovascular diseases, but also other diseases caused by 
abnormal TGF-β signaling. 
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The expression level of Adamts16 is up-regulated and correlated with the levels of Mmp2, 
Mmp9, Col1a1 and Col3a1 in the hearts from TAC mice with pressure overload-induced 
cardiac hypertrophy and heart failure. (A) Western blot analysis for ADAMTS16 using heart 
protein extracts from TAC mice and control Sham mice. Tubulin was used as loading control. 
Data are shown as mean ± SD. **P<0.01 (n=6). (B) Real-time RT-PCR analysis for 
Adamts16 using total cardiac RNA samples from 16 week old TAC mice and control Sham 
mice. Data are shown as mean ± SD. **P<0.01 (n=6). (C) Real-time RT-PCR analysis 
showed that the expression levels of Adamts16 significantly correlated with the levels of 
Mmp2 (r=0.84), Mmp9 (r=0.78), Col1a1 (r=0.75) and Col3a1 (r=0.79) in TAC mice. P<0.05 
(n=12). Statistical analysis was carried out by a Student’s t-test. 
 
 
Figure 2  
Overexpression of ADAMTS16 accelerates the activation of cardiac fibroblasts 
(differentiation of cardiac fibroblasts into myofibroblasts with increased -SMA). (A) 
Real-time RT-PCR analysis for Acta2 (encoding -SMA) in mouse cardiac fibroblasts 
transfected with pcDNA3.1 or a mammalian expression plasmid for human ADAMTS16 and 
treated with Ang II (48 hours) or negative control buffer. (B) Immunostaining analysis 
of-SMA for mouse primary cardiac fibroblasts treated as in (A). Scale bar =12.5 μm. (C) 
Quantification of immunostaining images as in (B). (D) Western blot analysis for -SMA 
using protein extracts from mouse cardiac fibroblasts treated as in (A). (E) Quantification of 
Western blotting data as in (D). (F) Collagen lattice contraction analysis of mouse cardiac 
fibroblasts treated as in (A). (G) Quantification of collagen lattice contraction data as in (F). 
(H) Migration of cardiac fibroblasts treated as in (A) using scratch wound assays. (I) 
Quantification of scratch wound data as in (H). Data are shown as mean ± SD. *P < 0.05, 
**P<0.01 (n=6/group). Statistical analysis was carried out by a one-way ANOVA test. 
 
 
Figure 3  
ADAMTS16 interacts with LAP-TGF-β1. (A) Schematic diagram showing the major 
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between TSP1 and the TSP1-domain of ADAMTS16. (C) Alignment of sequences of the 
proximal TSP1-domain of ADAMTS16 and thrombospondin-1 (TSP1).  The homologous 
amino acid sequences at the WxxW and KRFK/RRFR motifs responsible for binding to the 
LAP are marked. (D) Schematic diagram showing the predicted interaction between 
ADAMTS16 and LAP-TGF-β via the WxxW and RRFR motifs. (E) Co-IP analysis using 
cellular protein extracts from mouse primary cardiac fibroblasts with co-expression of 
ADAMTS16 and LAP-TGFβ. An anti-ADAMTS16 antibody (Ab-Adam) was used for 
immunoprecipitation and an anti-FLAG antibody recognizing LAP-TGFβ was used for 
immunoblotting. (F) Reciprocal Co-IP analysis. An anti-FLAG antibody recognizing 
LAP-TGFβ (Ab-FLAG) was used for immunoprecipitation and an anti-ADAMTS16 antibody 




ADAMTS16 induces the activation of TGF-β. (A) Western blot analysis showed that 
overexpression of ADAMTS16 decreased the level of LAP-TGF- in mouse cardiac 
fibroblasts transfected with LAP-TGF-β. The experiment was independently repeated for 
three times (n=6). (B) Schematic diagram showing wild type (WT) ADAMTS16 and mutant 
ADAMTS16 with the RRFR motif mutated into IIFI. (C) Western blot analysis showed that 
overexpression of mutant ADAMTS16 did not affect the level of LAP-TGF- in mouse 
cardiac fibroblasts transfected with LAP-TGF-β (n=6). (D) Co-IP analysis showed that the 
interaction between LAP-TGF-βandADAMTS16 was reduced in mouse cardiac fibroblasts 
by mutation IIFI (n=6). (E) ELISA for measurements of active TGF-(pg/ml) in the 
supernatant of mouse cardiac fibroblasts co-transfected with LAP-TGF- and 
WT-ADAMTS16 or Mut-ADAMTS16. Data are shown as mean ± SD. **P<0.01 (n=4). 
Statistical analysis was carried out by a one-way ANOVA test. (F) ELISA for measurements 
of total TGF-β (acid treated) in the supernatant of mouse cardiac fibroblasts treated as in (E). 
(G) Luciferase assays for TGF-β-mediated transcription activation in HeLa cells.  Data are 
shown as mean ± SD. **P<0.01 (n=4/group). Statistical analysis was carried out by a 
one-way ANOVA test. (H) Effects of TGF-β NAb on TGF-β-mediated transcription 
activation in HeLa cells. Data are shown as mean ± SD. **P<0.01, NS, not significant 
(n=4/group). Statistical analysis was carried out by a one-way ANOVA test. (I) Western blot 
analysis showed that knockdown of Adamts16 expression by siRNA significantly increased 
the level of LAP-TGF-β in mouse cardiac fibroblast (n=6/group).  (J) ELISA for 
measurements of the level of active TGF-βin the supernatant of mouse cardiac fibroblasts 
transfected with Adamts16 siRNA or siNC. Data are shown as mean ± SD. **P<0.01 (n=4). 
Statistical analysis was carried out by a Student’s t-test. (K) ELISA for measurements of the 
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TGF-β-mediated transcriptional activation by Adamts16 siRNA. Data are shown as mean ± 
SD. **P<0.01 (n=4).  Statistical analysis was carried out by a Student’s t-test. 
 
 
Figure 5  
The RRFR peptide inhibits the interaction between ADAMTS16 and LAP-TGF-β and 
induces the activation of TGF-β. (A) Co-IP analysis for the interaction between Adamts16 
and LAP-TGF-β in mouse cardiac fibroblasts treated with different concentrations of the 
RRFR peptide.  An anti-FLAG antibody was used for immunoprecipitation and an 
anti-ADAMTS16 antibody was used for immunoblotting (IB). (B) Western blot analysis 
showing the effect of the RRFR peptide on the level of LAP-TGF-β in mouse cardiac 
fibroblasts  Data are shown as mean ± SD. **P<0.01 (n=6). Statistical analysis was 
carried out by a one-way ANOVA test. (C) ELISA showing the effect of the RRFR peptide on 
the level of active TGF-β in the supernatant of mouse cardiac fibroblasts.  Data are shown as 
mean ± SD. **P<0.01 (n=5). Statistical analysis was carried out by a two-way ANOVA 
analysis. NS indicates not significant. (D) Luciferase assays for TGF-β-mediated 
transcriptional activation in HeLa cells transfected with the TGF-β-responsive 3TPE 
luciferase reporter gene and treated with Adamts16 siRNA or negative control siRNA (siNC) 
for 18 hours. Cells were then incubated with the RRFR peptide or IIFI peptide for 18 hours, 
and sued for luciferase assays. Data are shown as mean ± SD. **P<0.01 (n=5). Statistical 
analysis was carried out by a two-way ANOVA analysis. NS indicates not significant.  
 
 
Figure 6  
The RRFR peptide accelerates cardiac hypertrophy. (A) Morphology of the hearts from Sham 
mice and TAC mice injected with the RRFR peptide in combination with or without TGF-β1 
NAb for 8 weeks. Scale bar = 1 mm. (B) Echocardiographic data showing left ventricular 
ejection fractions (LVEF, n=8/group). (C) Ratio of heart weight to tibia length (HW/TL, 
n=8/group). (D) Systolic blood pressure (mmHg, n=8/group). (E) Plasma ANF levels 
(n=8/group). Data are shown as mean ± SD. **P < 0.01 vs. Sham+vehicle+IgG group; 
#P < 0.05, ##P < 0.01 vs. TAC+vehicle+IgG group; §P < 0.05, vs. TAC+vehicle+IgG group; 
††P<0.01 vs. TAC+RRFR+IgG group. NS indicates not significant. Statistical analysis was 














The RRFR peptide accelerates cardiac fibrosis. (A) Masson staining (upper panel) and typical 
Sirius Red staining (lower panel) of the hearts in Sham mice and TAC mice with 
pressure-overloading for 8 weeks.  The collagenous area and myocardial fibrosis of the 
hearts are graphed for different groups of mice (n=8). Scale bar = 100 μm, and the quantified 
data are shown at the right (B) and (C).  (D), (E), (F) and (G) represent the effects of the 
RRFR peptide treatment combined with TGF-β1 NAb or IgG on the mRNA expression levels 
for Col1a1, Col3a1, Mmp2 and Mmp9 in mice after 8 weeks of TAC (n=8). (H) Western blot 
analysis showing the effects of the combined treatment of the RRFR peptide with TGF-β1 
NAb or IgG on levels of SMAD2/3 phosphorylation in mice after 8 weeks of TAC operation 
(n=8). The quantified data are shown at the right (I) and (J). (K) Diagram showing the 
molecular signaling pathway for ADAMTS16 as a central activator of TGF-β to accelerate 
cardiac fibrosis, cardiac hypertrophy and heart failure.  Data are shown as mean ± SD. 
**P < 0.01 vs. Sham+vehicle+IgG group; #P < 0.05, ##P < 0.01 vs. TAC+vehicle+IgG group; 
§P < 0.05, §§P < 0.01, vs. TAC+vehicle+IgG group; ††P<0.01 vs. TAC+RRFR+IgG group. NS 
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